Significant Medicare Part D Subsidy Changes Impacting Premiums and Drug Costs

In late July 2026, the Centers for Medicare and Medicaid Services (CMS) announced the conclusion of a subsidies program within Medicare Part D aimed at controlling drug costs for beneficiaries. This significant policy change was part of CMS's annual release of Medicare's national average bid amount and received widespread media attention due to its potential impact on premiums.

CMS Administrator Mehmet Oz elaborated via social media, highlighting that the cessation of previous administration subsidies for insurance companies necessitated market adjustments. Despite this, most Medicare participants are expected to see minimal premium increases, typically under $10 monthly, with some even experiencing reductions. Market stability improvements aim to sustain access to affordable plans, facilitating reductions in prescription drug pricing.

This policy shift is part of the 2022 Inflation Reduction Act's broader strategy to leverage Medicaid's negotiating power with pharmaceutical companies for reducing drug expenses. In an October 2023 Department of Health and Human Services update, several drug manufacturers committed to negotiated pricing, with plans to include more medications over time.

The funding realignment transitions government subsidies from retroactive reconciliations to upfront risk-adjusted payments, optimizing cost management within available resources for insurance carriers. A premium stabilization mechanism aims to limit average increases to around $2 per month, transitioning how plan bids correlate with enrollee premium modifications.

Approximately 25% of enrollees will experience stable or reduced premiums, while 30% will see increases of less than $10, and about 45% could encounter hikes between $11 and $20 monthly. These adjustments may influence enrollment behaviors, potentially increasing interest in Medicare Advantage plans that often include drug benefits without extra premiums.

According to Juliette Cubanski of KFF, while the subsidies previously buffered economic pressures, their removal may lead to significant premium hikes for those in stand-alone drug plans. Nevertheless, these financial aids did not fully counteract challenges like rising drug prices and the growing utilization of high-cost specialty medications.